Genmab
Healthcare & Life Sci
Company overview
Genmab is a Danish biotechnology company that develops antibodies to treat cancer and other diseases. Darzalex treats cancer, Kesimpta treats autoimmune diseases, and Rybrevant is a bispecific antibody used in cancer treatment. The company also markets several other approved antibodies, including Talvey, Tecvayli, and Tivdak. Genmab is based in Copenhagen, Denmark.
Genmab was founded in 1999. It is a public company, traded on Nasdaq Copenhagen and Nasdaq in the US under the ticker GMAB. In 2023 it had 2,204 employees and revenue of DKK 16.474 billion. Revenue that high with a team that size means each approved drug carries a lot of weight for the company. Genmab is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Copenhagen, Denmark